Sugi Predict

Sugi Predict / Compounds / SCHEMBL6284365

SCHEMBL6284365

SCHEMBL6284365

NS(=O)(=O)CCNC(=O)OCc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.63
▸ SMN1; SMN2 Q16637 1/20 0.63
▸ CA1 P00915 5/20 0.61
▸ CA2 P00918 5/20 0.61
▸ CA12 O43570 3/20 0.61
▸ CA9 Q16790 3/20 0.61
▸ HTT P42858 1/20 0.60
▸ TGM2 P21980 1/20 0.53
▸ SLC1A3 P43003 1/20 0.53
▸ SLC1A1 P43005 1/20 0.53
▸ L3MBTL1 Q9Y468 2/20 0.52
▸ KEAP1 Q14145 2/20 0.52
▸ NFE2L2 Q16236 2/20 0.52
▸ MAPT P10636 1/20 0.51
▸ KAT2B Q92831 1/20 0.50
▸ MEN1 O00255 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ PLAU P00749 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13020423 0.88 LMNA (0.60) LMNASMN1; SMN2CA1CA2CA12
SCHEMBL4061201 0.86 LMNA (0.65) LMNASMN1; SMN2CA1CA2CA12
SCHEMBL3798700 0.85 LMNA (0.63) LMNASMN1; SMN2CA1CA2CA12
SCHEMBL2795077 0.85 LMNA (0.63) LMNASMN1; SMN2CA1CA2CA12
SCHEMBL10873001 0.85 LMNA (0.63) LMNASMN1; SMN2CA1CA2CA12
SCHEMBL17860175 0.84 LMNA (0.58) LMNASMN1; SMN2CA1CA2CA12
SCHEMBL3798701 0.84 LMNA (0.61) LMNASMN1; SMN2CA1CA2CA12
SCHEMBL13055383 0.84 LMNA (0.80) LMNASMN1; SMN2CA1CA2CA12
SCHEMBL19343344 0.82 LMNA (0.68) LMNASMN1; SMN2CA1CA2CA12
SCHEMBL5258117 0.81 LMNA (0.58) LMNASMN1; SMN2CA1CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240182503-A1 MACROCYCLE COMPLEMENT FACTOR B INHIBITORS ALEXION PHARMACEUTICALS, INC. (US) 2024-06-06 — — US disclosed
EP-4277982-A1 MACROCYCLE COMPLEMENT FACTOR B INHIBITORS Alexion Pharmaceuticals, Inc. (US) 2023-11-22 — — EP disclosed
US-11738120-B1 Synthesis of taurolidine, purity profiles and polymorphs CORMEDIX INC. (US) 2023-08-29 — — US disclosed
US-11738120-B1 Synthesis of taurolidine, purity profiles and polymorphs CORMEDIX INC. (US) 2023-08-29 — — US disclosed
WO-2022155294-A1 MACROCYCLE COMPLEMENT FACTOR B INHIBITORS ALEXION PHARMACEUTICALS, INC. (US) 2022-07-21 — — WO disclosed
EP-3359541-B1 N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE ABBVIE OVERSEAS SARL (LU) 2020-08-05 — — EP disclosed
US-10647717-B2 N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use ABBVIE S.Á.R.L. (LU) 2020-05-12 — — US disclosed
US-10647717-B2 N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use ABBVIE S.Á.R.L. (LU) 2020-05-12 — — US disclosed
US-20190330207-A1 N-Sulfonylated-Pyrazolo[3,4-b]Pyridin-6-Carboxamides and Method of Use ABBVIE SARL (LU) 2019-10-31 — — US disclosed
US-20190330207-A1 N-Sulfonylated-Pyrazolo[3,4-b]Pyridin-6-Carboxamides and Method of Use ABBVIE SARL (LU) 2019-10-31 — — US disclosed
WO-2011035540-A1 4-(SUBSTITUTED ANILINO)QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS 齐鲁制药有限公司 (CN) 2011-03-31 — — WO disclosed
CN-100368394-C N- (2-aryl-propionyl) -sulfonamides and pharmaceutical compositions containing them DOMPE SPA (IT) 2008-02-13 — — CN disclosed
CN-1615833-A N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them DOMPE SPA (IT) 2005-05-18 — — CN disclosed
US-6887903-B1 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them DOMPE S.P.A. (IT) 2005-05-03 — — US disclosed
US-6881755-B2 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them Dompé S.p.A. (IT) 2005-04-19 — — US disclosed
US-20030216392-A1 N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them DOMPE S.P.A. 2003-11-20 — — US disclosed
EP-1123276-B1 N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM DOMPE SPA (IT) 2003-01-08 — — EP disclosed
CN-1324344-A N- (2-aryl-propionyl) -sulfonamides and pharmaceutical compositions containing them DOMPE SPA (IT) 2001-11-28 — — CN disclosed
EP-1123276-A1 N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM Dompe' S.P.A. (IT) 2001-08-16 — — EP disclosed
WO-2000024710-A1 N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM DOMPE' S.P.A. (IT) 2000-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190330207-A1 N-Sulfonylated-Pyrazolo[3,4-b]Pyridin-6-Carboxamides and Method of Use CFTR, CHRM3, P2RY1 LMNA 4540/4885SMN1; SMN2 793/4885CA1 4435/4885
US-20030216392-A1 N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them ELANE, MPO, FPR1 LMNA 2333/4885SMN1; SMN2 408/4885CA1 3899/4885
US-20240182503-A1 MACROCYCLE COMPLEMENT FACTOR B INHIBITORS CFB, CFH, C9 LMNA 1699/4885SMN1; SMN2 2268/4885CA1 4874/4885
US-10647717-B2 N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use CFTR, CHRM3, P2RY1 LMNA 4540/4885SMN1; SMN2 793/4885CA1 4435/4885
US-11738120-B1 Synthesis of taurolidine, purity profiles and polymorphs PTMA, MAPT, F2 LMNA 174/4885SMN1; SMN2 1791/4885CA1 4065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.